secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0000950170-23-005830
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma completes NASH trial enrollment, on track for CML and obesity trials in H2 2023
--------------------------------------------------------------------------------

- Completed enrollment in Phase 2a DUET trial of TERN-501 (THR-β agonist) for NASH; top-line data expected Q3 2023.
- On track to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in H2 2023; China Phase 1 update at major oncology conference.
- IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; first-in-human obesity trial expected H2 2023 with top-line data in 2024.
- FDA Type C meeting scheduled for May 2023 to discuss non-invasive endpoints for NASH development.
- Adjusted cash balance of $293M (including $112M Dec 2022 equity financing) expected to provide runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023005830/0000950170-23-005830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023005830/tern-20230302.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer